Tri Locum Partners L.P. 13F annual report

Tri Locum Partners L.P. is an investment fund managing more than $395 billion ran by Christabel Syham. There are currently 25 companies in Syham’s portfolio. The largest investments include Teva Pharmaceutical Inds Ltd and Argenx Se, together worth $73.5 billion.

$395 billion Assets Under Management (AUM)

As of 7th August 2024, Tri Locum Partners L.P.’s top holding is 2,550,307 shares of Teva Pharmaceutical Inds Ltd currently worth over $41.4 billion and making up 10.5% of the portfolio value. In addition, the fund holds 74,558 shares of Argenx Se worth $32.1 billion. The third-largest holding is Ascendis Pharma A/S worth $31.1 billion and the next is AMGEN worth $25.7 billion, with 82,271 shares owned.

Currently, Tri Locum Partners L.P.'s portfolio is worth at least $395 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Tri Locum Partners L.P.

The Tri Locum Partners L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Christabel Syham serves as the Chief Compliance Officer at Tri Locum Partners L.P..

Recent trades

In the most recent 13F filing, Tri Locum Partners L.P. revealed that it had opened a new position in AMGEN and bought 82,271 shares worth $25.7 billion. This means they effectively own approximately 0.1% of the company. AMGEN makes up 9.0% of the fund's Health Care sector allocation and has grown its share price by 23.9% in the past year.

The investment fund also strengthened its position in Teva Pharmaceutical Inds Ltd by buying 334,119 additional shares. This makes their stake in Teva Pharmaceutical Inds Ltd total 2,550,307 shares worth $41.4 billion.

On the other hand, there are companies that Tri Locum Partners L.P. is getting rid of from its portfolio. Tri Locum Partners L.P. closed its position in Silk Rd Med Inc on 14th August 2024. It sold the previously owned 1,083,605 shares for $19.9 billion. Christabel Syham also disclosed a decreased stake in Xenon Pharmaceuticals Inc by 0.5%. This leaves the value of the investment at $3.98 billion and 101,959 shares.

One of the smaller hedge funds

The two most similar investment funds to Tri Locum Partners L.P. are Castle Rock Wealth Management and Versant Capital Management, Inc. They manage $395 billion and $395 billion respectively.

Christabel Syham investment strategy

Tri Locum Partners L.P.’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 72.5% of the total portfolio value. The fund focuses on investments in the United States as 48.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 20% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $35.6 billion.

The complete list of Tri Locum Partners L.P. trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Teva Pharmaceutical Inds Ltd	15.08% 2,550,307	$41,442,489,000	10.48%
Argenx Se	166.46% 74,558	$32,062,922,000	8.11%
Ascendis Pharma A/S	102.15% 227,762	$31,062,182,000	7.85%
AMGEN Inc.	Opened 82,271	$25,705,574,000	6.50%
Natera Inc	21.29% 230,585	$24,970,050,000	6.31%
Axsome Therapeutics Inc	198.42% 306,513	$24,674,297,000	6.24%
Insmed Inc	Opened 316,501	$21,205,567,000	5.36%
Merus N.V	17.18% 335,514	$19,852,363,000	5.02%
Silk Rd Med Inc	Closed 1,083,605	$19,851,644,000
Regeneron Pharmaceuticals, Inc.	104.46% 17,516	$18,409,841,000	4.65%
Madrigal Pharmaceuticals Inc	22.49% 65,352	$18,309,016,000	4.63%
Inspire Med Sys Inc	465.54% 133,276	$17,836,327,000	4.51%
Avadel Pharmaceuticals plc	0.00% 1,189,518	$16,724,623,000	4.23%
Pfizer Inc.	Opened 596,919	$16,701,794,000	4.22%
United Therapeutics Corp	Opened 50,100	$15,959,355,000	4.04%
Legend Biotech Corp	25.64% 356,532	$15,790,802,000	3.99%
Merck Co Inc	Closed 119,200	$15,728,440,000
Vertex Pharmaceuticals, Inc.	Closed 35,598	$14,880,320,000
Baxter International Inc.	Closed 317,566	$13,572,771,000
Tandem Diabetes Care Inc	Closed 326,506	$11,561,577,000
Alnylam Pharmaceuticals Inc	Opened 45,000	$10,935,000,000	2.76%
Stevanato Group S.p.A.	Opened 565,422	$10,369,839,000	2.62%
Novo-nordisk A S	Opened 63,811	$9,108,382,000	2.30%
Vaxcyte, Inc.	Opened 113,344	$8,558,605,000	2.16%
Exact Sciences Corp.	Closed 90,000	$6,215,400,000
Lyra Therapeutics, Inc.	Closed 978,793	$6,088,092,000
Astria Therapeutics Inc	Closed 369,549	$5,201,402,000
Alpine Immune Sciences Inc	Closed 120,687	$4,784,033,000
Arcturus Therapeutics Hldgs	Closed 138,927	$4,691,565,000
Arcutis Biotherapeutics Inc	Closed 449,694	$4,456,468,000
Xenon Pharmaceuticals Inc	50.85% 101,959	$3,975,381,000	1.01%
Ocular Therapeutix Inc	Opened 514,642	$3,520,151,000	0.89%
Praxis Precision Medicines I	29.27% 75,319	$3,115,194,000	0.79%
Mind Medicine Mindmed Inc	0.65% 382,055	$2,754,617,000	0.70%
Korro Bio Inc	Opened 71,428	$2,419,266,000	0.61%
Perspective Therapeutics Inc	Closed 780,303	$928,561,000
Femasys Inc	No change 30,606	$34,891,000	0.01%
No transactions found
Showing first 500 out of 37 holdings